Anti-RNase L - Purified In vivo PLATINUM Functional Grade

Antibody Details

Product Details

Reactivity Species

Human/Hamster/Primate

Host Species

Mouse

Immunogen

Purified, full-length, recombinant, human RNaseL produced in insect cells.

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

< 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Next Day 2-8°C

Working Concentration

ELISA 1:100-1:2000

IHC-P 1:200-1:1000

WB 1:1000-1:4000

RRID

AB_2831733

Applications and Recommended Usage?
Quality Tested by Leinco

WB
ELISA

Other Applications Reported In Literature ?

IHC FFPE

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone 2E9 recognizes an epitope on human/hamster/primate RNaseL.

Antigen Distribution

RNase L is highly expressed in the spleen and thymus, followed by prostate, testis, uterus, small intestine, colon, and peripheral blood leukocytes.

Background

RNase L antibody, clone 2E9, recognizes the interferon (IFN)-inducible 2-5A-dependent ribonuclease L (RNase L), an endoribonuclease involved in antiviral signaling. It is widely expressed as a latent monomer in most mammalian tissues¹. 2’, 5’-oligoadenylate synthetase (OAS) is expressed following viral infection and exposure to IFN2. OAS proteins are activated by dsRNA, resulting in the production of 2’, 5’-linked oligoadenylates (2-5A), which bind to latent RNase L, inducing dimerization and activation2. RNase L inhibits viral replication by cleaving viral and ribosomal RNA^{3, 4} and inducing apoptosis in virus-infected cells^{5, 6}. RNase L is suggested to have antitumor effects, possibly through its pro-apoptotic activity⁷, and mutations in the RNASEL gene are associated with prostate cancer risk and progression^{8, 9}.

Antigen Details

Protein

RNaseL

PubMed

RNaseL

NCBI Gene Bank ID

6041

UniProt.org

Information on Uniprot.org

Research Area

Cell Biology

.

Immunology

.

Neuroinflammation

.

Neuroscience

References & Citations

1. Zhou A, et al. (2005) J Interferon Cytokine Res. 25(10):595-603

2. Silverman RH. (2007) Cytokine Growth Factor Rev. 18(5-6):381-8

3. Wreschner DH, et al. (1981) Nucleic Acids Res. 9(7):1571-81

4. Cooper DA, et al. (2014) Nucleic Acids Res. 42(8):5202-16

5. Castelli JC, et al. (1997) J Exp Med. 186(6):967-72

6. Zhou A, et al (1997) EMBO J. 16(21):6355-63

7. Xiang Y, et al. (2003) Cancer Res. 63(20):6795-801

8. Meyer MS, et al. (2010) Carcinogenesis. 31(9):1597-603

9. Silverman RH. (2003) Biochemistry. 42(7):1805-12

Technical Protocols